JOHNSON & JOHNSON (JNJ) - Price, trends, fundamentals and chart - Passport to Wall Street

JOHNSON & JOHNSON (NYSE: JNJ)

Overview

current price

$155.36

$155.36

change

2.11 | 1.38%

2.11 | 1.38%

Yesterday's Close

153.25

open

154.02

volume

10.36 M

30d. avg volume.

9.74 M

1 day

153.45 - 155.79

52 weeks

140.68 - 169.99

p/e

26.47

beta

0.4897

market cap

369.31 B

dividend yield

3.24%

Industry

-

News and Commentary

US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims A U.S. bankruptcy court in Texas has rejected Johnson & Johnson's

US Manufacturing Slips Into Contraction As Tariff-Driven Costs Hit Near 3-Year High The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass...

Market Update: Stocks Climb Higher on AI Optimism, Netflix Earnings Stocks climbed higher Wednesday, building on the previous session's gains, as investor optimism around artificial intelligence and Netflix

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outl... On Wednesday, Johnson & Johnson (

Market Update: Dow Climbs 500 Points on Softer Trump Tariff Expectations Stocks rose Tuesday as President Donald Trump's first-day actions regarding international trade were not issued on day one. The Dow Jones Industrial Average climbed over 500 poin...

Market Update: Dow Climbs 350 Points Ahead of Busy Earnings Week Stocks were mostly higher on Monday, with the Dow Jones Industrial Average outperforming the broader market, as market participants look ahead towards a busy week of fourth-quart...

Market Update: Dow Falls 300 Points as Third-Quarter Earnings Season Begins Stocks fell lower on Tuesday, off fresh record highs, as market participants navigated a slew of corporate earnings reports. The Dow Jones Industrial Average dropped over 300 poi...

Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Ou... On Tuesday, Johnson & Johnson (

Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson's

Listerine-Maker Kenvue's Stock Soars On Strong Q2 Sales From Its Essential Health Unit, Reaffirms An... Consumer health company Kenvue Inc. (

StockTwits

StockTwits